Welcome to our dedicated page for AMAR news (Ticker: AMAR), a resource for investors and traders seeking the latest updates and insights on AMAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMAR's position in the market.
Ainos, Inc. (OTC PINK:AIMD) has signed an exclusive agreement with Taiwan Carbon Nano Corporation (TCNT) to act as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit in Taiwan.
Following the emergency use authorization from the Taiwan Food and Drug Administration on June 7, Ainos aims to promote the kit regionally. The test provides results in 15 minutes with high sensitivity and specificity, featuring a unique smartphone tracking function.
Ainos, Inc. (formerly Amarillo Biosciences) announced on May 24, 2021, that the Financial Industry Regulatory Authority (FINRA) approved its name change and new ticker symbol AIMD. This change takes effect immediately, following a securities purchase transaction with Ainos, Inc. of the Cayman Islands. The company has engaged Donohoe Advisory Associates LLC to help evaluate U.S. National Securities Exchanges listing requirements. Ainos focuses on developing innovative healthcare products, including diagnostics for COVID-19 and other infections.
Ainos, Inc. (OTCBB:AMAR), formerly Amarillo Biosciences, Inc., has finalized a Securities Purchase Agreement with strategic investor Ainos, Inc. (Cayman Islands). The Company issued 100 million shares at $0.20 per share in exchange for patent assignments, expanding its authorized stock to 300 million shares. Following the transaction, Ainos KY owns approximately 70.39% of the Company’s outstanding shares. The new leadership aims to enhance the Company’s diagnostic capabilities, focusing on rapid test kits for various diseases, including COVID-19.
